Covidien — Merger or Acquisition (July 2014)
24 slides from Covidien's merger presentation, Jul 9, 2014
Slide 1: Town Hall Meeting
Town Hall Meeting July 9, 2014 Omar Ishrak Chairman and CEO Medtronic, Inc. Filed by Medtronic, Inc. (SEC File No.: 001-07707) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Covidien plc SEC Fi
Slide 2: Medtronic to Acquire Covidien
Medtronic to Acquire Covidien Creates the premier global medical technology and services company with unmatched breadth and patient reach
Slide 3: Agenda
Agenda Strategic Fit Combined Impact COVIDIEN About Medtronic Integration Guidelines Q&A
Slide 4: About Medtronic
About Medtronic
Slide 5: Fulfilling Unmet Medical Needs
Fulfilling Unmet Medical Needs
Slide 6: The Medtronic Mission: A Shared Sense of Purpose
The Medtronic Mission: A Shared Sense of Purpose To contribute to human welfare…alleviate pain, restore health, and extend life… To direct our growth in the areas of maximum strength and ability… To strive without reserve for the greatest reliability and quality… to be recognized as a company of ded
Slide 7: Universal Healthcare Needs
Improve Clinical Outcomes Expand Access Optimize Cost and Efficiency Universal Healthcare Needs
Slide 8: Strategies to Address Healthcare Needs
Economic Value Globalization Strategies Therapy Innovation Universal HC needs Improve clinical outcomes Expand access Optimize cost and efficiency Strategies to Address Healthcare Needs
Slide 9: Three Business Groups Address Broad Spectrum of Diseases
Three Business Groups Address Broad Spectrum of Diseases The data in this chart has been intentionally rounded to the nearest whole percentage and therefore does not sum to 100%. Cardiac Rhythm Disease Management 30% Coronary 11% Structural Heart 7% Endovascular Therapies 5% Diabetes 9% Surgical Tec
Slide 10: Strategic Fit
Strategic Fit
Slide 11: Combination Results in Strategic Diversification
Combination Results in Strategic Diversification Restorative Therapies Group Spine Neuromodulation Surgical Technologies Cardiac and Vascular Group Cardiac Rhythm Structural Heart Coronary Vascular Endovascular Diabetes Group Surgical Solutions Respiratory & Patient Care Vascular Therapies Restorati
Slide 12: A Strong Strategic Fit
Delivering strong launch cadence of meaningful therapies and procedures Addressing the inequities in healthcare access globally Becoming a leader in value-based healthcare by incorporating EV into our DNA & Uniquely positioned to expand our industry- leading franchises through our three differentiat
Slide 13: Three Key Benefits for Medtronic and Covidien
Three Key Benefits for Medtronic and Covidien Therapy Innovation Therapy Innovation 1. Strengthen and enhance Peripheral Vascular and Neuroscience portfolios 2. Leverage adjacencies in Medtronic Surgical Technologies and Covidien Surgical Solutions 3. Accelerate market adoption of early stage Covidi
Slide 14: Combined Company Immediately Accelerates Ability to Expand Global Access
Combined Company Immediately Accelerates Ability to Expand Global Access countries 150 + locations 300 + combined EM revenue $3.7B Covidien products such as surgical tools and capital equipment are adopted earlier in hospitals, becoming a base for Medtronic chronic disease therapies Combined R&D and
Slide 15: A Robust and Unmatched Integrated Health Solutions Partner
A Robust and Unmatched Integrated Health Solutions Partner Diagnostic, Surgical, and Critical Care Technologies Value primarily realized in hospital efficiency Chronic Disease Therapies Value primarily realized in post-acute setting Economic Value COVIDIEN
Slide 16: Integration Guidelines
Integration Guidelines
Slide 17: Guiding Principles for Integration
Guiding Principles for Integration • Continue to act as independent companies until transaction close • Keep focus and protect current business momentum in our respective companies • Plan for integration now to be ready for Day 1 post-close • Focus on creating lasting value beyond stated cost synerg
Slide 18: Integration Team Structure
Integration Team Structure Medtronic Medtronic Geoff Martha Bill Burke Medtronic Steering Committee Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Medtronic Cross-functional teams Commercial teams Functional teams Med
Slide 19: Combined Impact
Combined Impact
Slide 20: Transforming Healthcare Around the World to Improve More Lives Together
Transforming Healthcare Around the World to Improve More Lives Together: Every seconds $27 Billion Healthcare Leader 87,000+ Employees Life-Changing Impact for Millions of Patients
Slide 21: Q&A
Q&A
Slide 22: No Offer or Solicitation
NO OFFER OR SOLICITATION This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the
Slide 23: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to New Medtronic’s, Medtronic's and/or Covidien’s estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that
Slide 24: Town Hall Meeting
Town Hall Meeting Omar Ishrak Chairman and CEO Medtronic, Inc.